ORIENT BIO Valuation
Is A002630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A002630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A002630's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A002630's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A002630?
Key metric: As A002630 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A002630's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | ₩52.82b |
| Market Cap | ₩56.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A002630's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
A036180 GW VitekLTD | 1.6x | n/a | ₩53.9b |
A086040 Biotoxtech | 1.1x | n/a | ₩50.6b |
A238120 Aligned Genetics | 1.4x | n/a | ₩46.2b |
A245620 Eone Diagnomics Genome Center | 1.4x | n/a | ₩57.4b |
A002630 ORIENT BIO | n/a | n/a | ₩56.9b |
Price-To-Book vs Peers: Insufficient data to calculate A002630's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does A002630's PB Ratio compare vs other companies in the KR Life Sciences Industry?
| 2 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate A002630's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is A002630's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A002630's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
J2KBIO
₩54.5b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,830.00
7D
6.0%
1Y
n/a
Hugel
₩3.0t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩268,000.00
7D
-3.4%
1Y
75.9%
Dong-A ST
₩544.1b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩62,300.00
7D
-2.0%
1Y
8.6%